STUDY. A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo
|
|
- Cora Elliott
- 5 years ago
- Views:
Transcription
1 STUDY A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the Treatment of Childhood Vitiligo Veronica Lepe, MD; enjamin Moncada, MD; Juan Pablo Castanedo-Cazares, MD; Maria ertha Torres-Alvarez, MD; Carlos A. Ortiz; Antonio. Torres-Rubalcava, MD Objective: To assess the safety and efficacy of topical 0.1% tacrolimus vs 0.05% clobetasol propionate. Design: Randomized double-blind trial. Setting: Department of Dermatology, Hospital Central Dr Ignacio Morones Prieto, San Luis Potosí, México. Participants: From 20 children with vitiligo, 2 symmetrical lesions of about the same size and evolution time were selected. They were devoid of any topical or systemic therapy for 2 months prior to inclusion. Interventions: Treatment with topical tacrolimus and clobetasol for a 2-month period. Main Outcomes Measures: The grade of repigmentation was evaluated by color slides at baseline and again at every 2-week visit. The slides were analyzed by 2 clinicians unrelated to the study and by a morphometric digitalized computer program. Characteristics of pigment, time of response, symptoms, telangiectasias, and atrophy were evaluated every 2 weeks. Results: Eighteen (90%) of the 20 patients experienced some repigmentation. The mean percentage of repigmentation was 9.3% for clobetasol and 1.3% for tacrolimus. Lesions in 3 patients using clobetasol presented atrophy, and 2 lesions incurred telangiectasias; tacrolimus caused a burning sensation in 2 lesions. Conclusions: Tacrolimus proved almost as effective as clobetasol propionate to restore skin color in lesions of vitiligo in children. ecause it does not produce atrophy or other adverse effects, tacrolimus may be very useful for younger patients and for sensitive areas of the skin such as eyelids, and it should be considered in other skin disorders currently treated with topical steroids for prolonged periods. Arch Dermatol. 2003;139: From the Dermatology Department, Hospital Central Dr Ignacio Morones Prieto (Drs Lepe, Moncada, Castanedo-Cazares, and Torres-Alvarez), Public Health Department (Dr Torres-Rubalcava), School of Medicine, and the Graphic Design School (Mr Ortiz), Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. The authors have no relevant financial interest in this article. VITILIGO IS a common idiopathic, acquired, depigmenting disease of the skin and hair that affects 0.5% of the world s population. 1 Controversy still exists about its pathogenesis because factors other than immunologic ones have been implicated, such as the early cell death of vitiligo melanocytes related to their increased sensitivity to oxidative stress. 2 The idea that nitric oxide could lead to autodestruction of melanocytes resulting in skin depigmentation has been raised. 3 Also, the monoaminergic system has been implicated because of increased activity of some of its components and higher levels of catecholamine and its metabolites. Neuropeptide Y may play certain roles in the pathogenesis of vitiligo via neuroimmunity mechanisms or neuronal effects on the melanocytes. 5 More recently, reports of the participation of 1,25-dihydroxy-vitamin D 3 in the regulation of melanin synthesis and the demonstration of the receptors in the melanocytes for this vitamin have opened a new direction in therapy. 6 See also pages 571 and 651 However, experimental evidence shows that abnormal humoral and cellmediated immune mechanisms are probably the most commonly involved aspect of pathogenesis in this disease The relative success of clinical use of topical corticosteroids (a widespread therapeutic approach with response rates between 50% and 70%) supports this theory. 11 Tacrolimus is an immunosuppressor macrolide lactone capable of inhibiting the activation and maturation of T cells by means of blocking the action of calcineurin and interleukin (IL) 2, IL-, and IL-5 transcription. 12,13 It also enhances T-cell apop- 581
2 A into account recentness or remoteness of the onset of lesions (a VIDA of + indicates a lesion duration of 6 weeks; +3, a duration of 3 months; +2, six months; and +1, one year). 19 Our patients had not had any vitiligo therapy for 2 months prior to the study. Patients with segmental and mucosal vitiligo were excluded. A total of 20 patients were recruited; there were 16 girls and boys. Only 2 patients had a positive family history. The mean age was 9.5 years (range, -17 years). The mean duration of disease was 2.2 years. The mean percentage of total area affected by vitiligo was 12.2%. The localization of vitiligo was variable. Fifteen patients (75%) had a VIDA of +, and the other 5 had a VIDA of +3. METHODS Figure 1. Vitiligo-depigmented eyelids (in red) before (A) and after () treatment with one of the study medications. The patient s right eyelid and brow were treated with clobetasol propionate and showed 0.3% repigmentation; the patient s left eyelid and brow were treated with tacrolimus, and showed 36.0% repigmentation. tosis in vitro and down-regulates IL-8 keratinocyte surface receptors. 1 Systemic tacrolimus has been used in a number of applications, particularly to avoid graft rejection. 15 Topical tacrolimus is a safe and effective treatment for inflammatory skin diseases, particularly atopic dermatitis, psoriasis, pyoderma gangrenosum, alopecia areata, and other illnesses with immunologic disarrangement. 16 Limited data are available about topical bioavailability in humans when tacrolimus is applied to normal skin, although a number of studies have assessed blood levels following application to diseased skin. In a phase 1 study of patients with atopic dermatitis, the topical absorption of 0.3% tacrolimus ointment was found to be less than % of an equivalent oral dose given for immunosuppression. Pruritus, burning sensation, and erythema are the adverse reactions observed from topically applied tacrolimus. 17 We hypothesized that given its immunomodulatory properties and safer profile than corticosteroids, tacrolimus ointment might carry an improved benefit toxic effect ratio 18 and provide a new therapeutic alternative to topical corticosteroids in children with vitiligo. We know from experience that clobetasol is the most effective topical corticoid therapy for vitiligo because it very often produces pigmentation where other topical steroids have failed. For that reason we selected clobetasol propionate rather than other midpotency steroids for this trial. METHODS PATIENTS Twenty patients younger than 18 years with vitiligo but otherwise healthy were selected for the study. They all had a vitiligo index of disease activity (VIDA) greater than 3; VIDA is a useful measure to assess the activity of the disease and takes Information collected in the routine clinical history included patient sex, location and distribution of the disease, percentage of depigmentation, age at onset, family history, and disease activity. Informed consent was obtained from all patients, and the study was approved by the local institutional review board. Two lesions similar to each other in size and time of evolution were selected to apply either 0.1% tacrolimus ointment (Protopic Ointment, Fujisawa Healthcare Inc, Deerfield, Ill) or 0.05% clobetasol propionate (Lobevat Cream; Stiefel Laboratories Inc, Coral Gables, Fla) twice a day, in a double-blind randomized way. The medications were in exactly the same containers, packed by a person unaware of the study. The total amount of medication used ranged between 20 and 0 g. Patients were evaluated every 2 weeks, and repigmentation and adverse effects were recorded. Color slides of the lesions were taken at the beginning and end of the treatment period. The slides were analyzed visually by 2 clinicians not involved in the study and by computer using Corel Draw, version 9.0 (Corel Corporation, Ottawa, Ontario). For the computer analysis, each of the digitalized pictures was subjected to morphometry analysis (Figure 1). The entire lesion was given a 0% score at the beginning of the study to indicate a baseline of no repigmentation. A second percentage value was assigned at the end of the study to represent the level of repigmentation. The categories of repigmentation were as follows: none (0%), poor (1%-25%), moderate (26%-50%), good (51%-75%), and excellent ( 75%). 20 STATISTICAL ANALYSIS To assess the size of the sample, we hypothesized that 95% of patients using clobetasol and 0% of patients using tacrolimus would reach some degree of repigmentation; using these figures, we determined that we needed 20 subjects. 21 The method of randomization was the technique of permuted block randomization for right or left selection. 22 Evaluation of the new pigment was done by the Kolmogorov-Smirnov test for clinical observation and the paired t test for digital observation. We compared the clinicians visual evaluations and the digitalizationmorphometry findings using the test of consistency. 23 The error differences between the medications had a normal distribution (W=0.965; P=.65); then a paired t test was applied (P=.005). 2 RESULTS Eighteen (90%) of our 20 patients achieved some repigmentation with each treatment (Figure 2). oth medications were very well tolerated during the 2 months of the study. The percentage of repigmentation with clo- 582
3 A A Figure 2. Extent of the vitiligo-depigmented area before (A) and after () treatment with one of the study medications is outlined in red in the top photographs and fully red shaded in the bottom. The patient s left eye was treated with tacrolimus and the right eye, clobetasol propionate. oth treatments resulted in significant improvement. Figure 3. A, Vitiligo depigmentation is apparent on the brows and lids of this patient before treatment., The condition is much improved after treatment. oth the clobetasol (patient s right eye) and tacrolimus (left eye) treatments produced excellent ( 75%) repigmentation. No. of Patients Clobetasol Propionate Nil Poor Moderate Repigmenting Grade betasol was 9.3% vs 1.3% with tacrolimus. With both treatments, the new pigment was conserved and the best effects of repigmentation were observed in the face and areas with greater density of hair follicles. Neither treatment produced pigment on the dorsum of the hands or areas devoid of hair follicles. With clobetasol, perifollicular islands of pigment were observed after 3 weeks; more than 75% overall repigmentation was seen in 5 (25%) of the clobetasoltreated patients. Of these, none showed complete repigmentation. Most of the patients using clobetasol (0%) experienced from 51% to 75% repigmentation in areas such as the axillae, legs, and abdomen areas where clobetasol showed an advantage over tacrolimus. No change of coloration was observed in 2 patients (10%); these 2 cases involved the dorsal hand areas. Tacrolimus produced more than 75% repigmentation in 5 patients, most of this on facial areas (Figure 3). Two patients (10%), the same 2 who showed no repigmentation from clobetasol, showed no change of pigmentation with tacrolimus. For those patients who experienced repigmentation, it first appeared after the third week, and the new pigment color was a mix between the color of the patient s normal skin and the color of the lesion. It was homogeneous and in centripetal form (Figure ). Clinical evaluation of the results showed no statistically significant differences between treatments (P.05, Kolmogorov-Smirnov test). However, computerized morphometric evaluation showed that tacrolimus was a significantly more effective treatment (P=.005, paired t test). The results obtained by the 2 clinicians not related to the study were compared and subjected to the test of consistency, 23 with the following results: =0.70 for clobetasol; =0.6 for tacrolimus. To prove the dependability of the computer program, the results of these 2 clinicians were compared against the computer results, with the following outcome: =0.93 and 0.79 for clobetasol; =0.7 and 0.51 for tacrolimus. These data show agreement for both kinds of observations. Atrophy was reported in 3 patients (15%) and telangiectasias in 2 (10%) after the eighth week of treatment with clobetasol, when approximately 20 to 30 g of medication had been consumed. urning sensations (that did not preclude continuation of therapy) were reported in 2 (10%) of the patients treated with tacrolimus during the first 2 weeks of treatment (Table). COMMENT Tacrolimus For the past 2 decades, monotherapy with topical steroids has been the most common treatment for vitiligo in children. The range of response has been between 20% and 90% improvement, usually not a complete 8 Good Excellent Figure. Eighteen (90%) of the 20 patients experienced some improvement of skin color with both treatments. Comparison between the 2 medications shows similar results except in the good category (51%-75% repigmentation). 583
4 Characteristics of Patients, Repigmentation, and Adverse Effects Repigmentation, % Adverse Effects Sex/Age, y Total ody Involvement, % VIDA Score Treated Area Evolution Time Clobetasol Tacrolimus Clobetasol Tacrolimus M/17 + Hands 2 mo 0 0 F/ Face 3 y M/ Legs 2 y F/ Face 2 y F/5 5 + Face 3 y Atrophy urning F/ Elbows 10 y F/ Face 8 y Teleangiectasia M/6 5 + Abdomen 2 y M/ Elbows 2 y F/ Abdomen 1 y M/ Legs y F/ Face 2 y urning F/ 5 + Hands 1 y 0 0 F/ 5 + Face 1 y Atrophy F/ Legs mo F/ Thorax 6 mo F/ Face 8 mo Atrophy F/6 3 + uttocks 1 y F/ Axillae mo Telangiectasia F/9 5 + Thorax 3 mo Abbreviation: VIDA, vitiligo index of disease activity. cure. 11 Adverse effects and poor efficacy have led to the search for new alternatives. While treatment with combinations of steroids and retinoids can avoid atrophy, retinoids are not well tolerated by children because of skin irritation. Therapy with systemic psoralens and UV-A irradiation is not used in children, and the topical variant is cumbersome and carries some risk. The new phototherapeutic approach with narrowband UV- irradiation may prove useful for children with vitiligo. 25 The search for substances with the benefits of topical steroids but without the well-known adverse effects seems to be producing results: calcipotriol for psoriasis and tacrolimus and other macrolides for inflammatory dermatoses. 26 Calcipotriol has also been shown to be 77% effective in treating adults with vitiligo, but there are no data for children with this disease. 27 In the present study, we compared treatment with tacrolimus and clobetasol propionate for repigmenting different areas of the body affected by vitiligo and found very similar results. The risk for adverse effects with both drugs was reduced due to frequent observation and the short duration of the study. Additionally, the hyperpigmented borders frequently seen in the repigmented skin of patients treated with clobetasol did not occur in those treated with tacrolimus. The tacrolimus repigmentation was homogeneous and not composed of confluent spots. Certainly the main point in the comparison made in this study was the absence of atrophy in lesions treated with tacrolimus. Regarding the question of tacrolimus penetration into noninflamed skin, the fact that pigmentation was obtained with this medication speaks in favor of penetration. Certainly there is no hyperkeratosis in vitiligo that could preclude incursion of the drug into the skin. In our study, the results were evaluated by digital morphometry, which we believe provides a high degree of certainty. Pigment obtained in the study was sustained throughout the period of observation. It remains to be seen whether the newly formed color remains over the long term. We believe that the present study is the first to show the usefulness of tacrolimus in treating vitiligo in children. It would be interesting to see whether longer periods of therapy, combinations of tacrolimus with other topical agents, or increased concentrations of tacrolimus could produce better results than those obtained in this series and whether the negative results obtained in acral areas could be overturned with any of these approaches. Accepted for publication November 12, This study was supported in part by the Dermatology Department at the Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. Corresponding author and reprints: enjamin Moncada, MD, Dermatology Department, School of Medicine, Universidad Autónoma de San Luis Potosí, 205 V Carranza Ave, Zona Universitaria, 78210, San Luis Potosí, SLP, Mexico ( moncadab@uaslp.mx). REFERENCES 1. Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38: Jimbow K, Chen H, Park JS, Thomas PD. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo. r J Dermatol. 2001;1: Rocha IM, Guillo LA. Lipopolysaccharide and cytokines induce nitric oxide synthetase and produce nitric oxide in cultured normal human melanocytes. Arch Dermatol Res. 2001;293: Cucchi ML, Frattini P, Santagostino G, Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res. 2000;13:
5 5. Lazarova R, Hristakieva E, Lazarov N, Shani J. Vitiligo-related neuropeptides in nerve fibers of the skin. Arch Physiol iochem. 2000;108: Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralens plus ultraviolet A in the treatment of vitiligo. r J Dermatol. 2001;15: Ghoneum M, Grimes EP, Gill G, Kelly AP. Natural cell-mediated cytotoxicity in vitiligo. J Am Acad Dermatol. 1987;17: Naughton GK, Reggiardo D, ystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986;15: Halder RM, Walters CS, Johnson A, Chakrabarti SG, Kenney JA Jr. Aberration in T lymphocytes and natural killer cells in vitiligo: a flow cytometric study. JAm Acad Dermatol. 1986;1: Grimes PE, Ghoneum M, Stockton T, Payne C, Kelly AP, Alfred L. T cell profiles in vitiligo. J Am Acad Dermatol. 1986;1: Njoo MD, Spuls PI, os JD, Westerhof W, ossuyt PM. Nonsurgical repigmentation therapies in vitiligo. Arch Dermatol. 1998;13: Duncan JL. Differential inhibition of cutaneous T-cell mediated reactions and epidermal cell proliferation by cyclosporine A, FK-506, and rapamycin. J Invest Dermatol. 199;102: Ahmed M, Venkataraman R, Logar AJ, et al. Quantitation of immunosuppression by tacrolimus using flor cytometric analysis of interleukin-2 and interferongamma inhibition in CD8(-) and CD8(+) peripheral blood T cells. Ther Drug Monit. 2001;23: Hashimoto Y, Matsuoka A, Kawakami M, Nakashima K, Eguchi T. Novel immunosuppressive effect of FK506 by augmentation of T-cell apoptosis. Clin Exp Immunol. 2001;125: Ruzicka T, Assmann T, Homey. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol. 1999;135: Azbawsi E, Costner M, Cohen J, Cockerell CJ. Tacrolimus: pharmacology and therapeutic uses in dermatology. Int J Dermatol. 2000;39: Alaiti S, Kang S, Fiedler CV, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38: Nasr IS. Topical tacrolimus in dermatology. Clin Exp Dermatol. 2000;25: Njoo MD, Das PK, os JD, Westerhof W. Association of the Köbner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol. 1999;135: Khalid M, Mujtaba G, Tahir SH. Comparison of 0.05% clobetasol propionate cream and topical puvasol in childhood vitiligo. Int J Dermatol. 1995;3: Hulley E, Cummings SR. Estimating sample size and power. In: rowner SW, lack D, Newman T, Hulley S, eds. Designing Clinical Research: An Epidemiologic Approach. 2nd ed. altimore, Md: William & Wilkins; 1988: Gore SM. Assessing clinical trials restricted randomisation. r Med J (Clin Res Ed). 1981;282: Kramer MS, Feinstein AR. Clinical biostatistics of concordance. Clin Pharmacol Ther. 1981;29: Sackett DL, Haynes R, Guyatt GH, Tugwell P. The clinical examination. In: Sackett DL, Haynes R, Guyatt GH, Tugwell P, eds. Clinical Epidemiology: A asic Science for Clinical Medicine. 2nd ed. oston, Mass: Little rown & Co Inc; 1991: Njoo MD, os JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UV radiation therapy. J Am Acad Dermatol. 2000;2: Assmann T, Homey, Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology. 2000;7: Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralens plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? a placebocontrolled double-blind study. r J Dermatol. 2001;15: ARCHIVES Features 1. Free color publication if color illustrations enhance the didactic value of the article. 2. Rapid publication. The time from acceptance to publication is 3 months. 3. Expedited review on request from authors.. Archives Express. Manuscripts with high priority can be reviewed, accepted, and published within 6 to 8 weeks. 5. Research Trainee Award of $1000 for the resident or fellow who is the first author of the best research paper of the past year. 6. Dermatologic Surgery Trainee Award of $1000 for the resident or fellow who is the first author of the best article on surgical dermatology published in the past year. 585
Vitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationEfficacy and Safety of Topical Tacrolimus (0.03%) in the Treatment Localized Vitiligo
Original Article Efficacy and Safety of Topical Tacrolimus (0.03%) in the Treatment Localized Vitiligo Husain MA 1, Alam MN 2, Rahim R 3, Joarder Y 4, Wahidujjaman 5, Ferdous M 6 Abstract Vitiligo is an
More informationOriginal Policy Date
MP 2.01.58 Light Therapy for Vitiligo Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Created with literature search/12:2013 Return to Medical Policy
More informationFollow this and additional works at: Part of the Skin and Connective Tissue Diseases Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2016 Is Narrowband UVB Phototherapy in Combination
More informationBroad-band pulsed UVB and topical tacrolimus treatment for localized vitiligo -our experience.
ORIGINAL PAPERS 134 Broad-band pulsed UVB and topical tacrolimus treatment for localized vitiligo -our experience. Alexia Díaz Mathé 1, Virginia Mariana González 2, Verónica Llorca 1, Kamelia Losada 3,
More informationAn Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma
An Efficacy Study of 3 Commercially Available Hydroquinone 4% Treatments for Melasma Pearl E. Grimes, MD Melasma is a common disorder of hyperpigmentation typically characterized by relatively symmetric
More informationA Retrospective Study of 231 Japanese Vitiligo Patients with Special Reference to Phototherapy
2014;22(1):13-18 CLINICAL ARTILCE A Retrospective Study of 231 Japanese Vitiligo Patients with Special Reference to Phototherapy Akiko Yoshida, Atsushi Takagi, Ayako Ikejima, Hiroshi Takenaka, Tatsuo Fukai,
More informationCurrent state of vitiligo therapy evidence-based analysis of the literature
DOI: 10.1111/j.1610-0387.2007.06280.x Review Article 467 Current state of vitiligo therapy evidence-based analysis of the literature Tobias Forschner, Stefan Buchholtz, Eggert Stockfleth Klinik für Dermatologie,
More informationMaintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study
ORIGINAL ARTICLE Maintenance Therapy of Adult Vitiligo with 0.1% Tacrolimus Ointment: A Randomized, Double Blind, Placebo Controlled Study Marine Cavalié 1, Khaled Ezzedine 2, Eric Fontas 3, Henri Montaudié
More informationProspective Study of Response to NBUVB in Various Forms of Vitiligo in Different Age Groups.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 2 Ver. IV (Feb. 2016), PP 12-16 www.iosrjournals.org Prospective Study of Response to NBUVB
More informationVitiligo is an acquired cutaneous disorder of
Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo Lubomira Scherschun, MD, Jane J. Kim, MD, and Henry W. Lim, MD Detroit, Michigan Background: The treatment of vitiligo remains
More informationA Vitiligo Update for Pharmacists: Current Practices and Future Advances
A Vitiligo Update for Pharmacists: Current Practices and Future Advances Dalal Hammoudi Halat, RPh, MSc, PhD Assistant Professor School of Pharmacy, Lebanese International University Disclosure Dalal Hammoudi
More informationนพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด
Vitiligo Vitiligo Update Acquired pigmentary disorder Depigmented macules and patches นพ.วาสนภ วช รมน หน วยโรคผ วหน ง คณะแพทยศาสตร โรงพยาบาลรามาธ บด Prevalence The prevalence of vitiligo is often said
More informationClinical Study Narrow-Band Ultraviolet B versus Oral Minocycline in Treatment of Unstable Vitiligo: A Prospective Comparative Trial
Dermatology Research and Practice, Article ID 240856, 4 pages http://dx.doi.org/10.1155/2014/240856 Clinical Study Narrow-Band Ultraviolet B versus Oral Minocycline in Treatment of Unstable Vitiligo: A
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationThis PDF is available for free download from a site hosted by Medknow Publications
Net Study Comparison of clinical efficacy of topical tazarotene.1% cream with topical clobetasol propionate.5% cream in chronic plaque psoriasis: A double-blind, randomized, right-left comparison study
More informationCorrespondence should be addressed to Juan Pablo Castanedo-Cazares,
Dermatology Research and Practice Volume 212, Article ID 33275, 6 pages doi:1.1155/212/33275 Clinical Study Double-Blind, Placebo-Controlled, Randomized Study Comparing.3% Calcitriol with.1% Tacrolimus
More informationVitiligo. Vasanop Vachiramon, MD. Assistant professor Division of Dermatology, Ramathibodi Hospital
Vitiligo Vasanop Vachiramon, MD. Assistant professor Division of Dermatology, Ramathibodi Hospital Vitiligo Acquired pigmentary disorder Depigmented macules and patches Prevalence The worldwide prevalence
More informationGLOSSARY of research terms
GLOSSARY of research terms SETTING PRIORITIES FOR VITILIGO RESEARCH - WORKSHOP Thursday 25 th March 2010 Types of studies Case Series: A study reporting on a consecutive collection of patients, treated
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A AA. See Alopecia areata. Acrofacial vitiligo presentation of, 135, 136 AD. See Atopic dermatitis. Adaptive immunity and vitiligo, 258
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationAtopic dermatitis/ eczema (a condition that makes skin red and itchy):
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Atopic dermatitis/ eczema (a condition that makes skin red and itchy): Atopic dermatitis (AD) is a common skin condition with
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationTriamcinolone and vitiligo
P ford residence southampton, ny Triamcinolone and vitiligo Dermatologica. 1970;140(3):195-206. Treatment of localized vitiligo with intradermal injections of triamcinolone acetonide. Kandil E. PMID: 5414362;
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationVitiligo: new etiology-based treatments
Review Article Vitiligo: new etiology-based treatments Abdul Hameed, Zahida Rani, Atif Hasnain Kazmi Department of Dermatology, King Edward Medical College/ Mayo Hospital, Lahore Abstract Vitiligo is an
More information50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate).
DUPISOR Composition Gel 50 microgram/g Calcipotriol and 500 microgram/g betamethasone (as dipropionate). Action Calcipotriol is a non-steroidal antipsoriatic agent, derived from vitamin D. Calcipotriol
More informationTreatment of segmental vitiligo with normal-hair follicle autograft
Original Article Medical Journal of the Islamic Republic of Iran, Vol. 27, No. 4, Nov 2013, pp. 210-214 Treatment of segmental vitiligo with normal-hair follicle autograft MirHadi Aziz Jalali 1, Babak
More informationTherapeutic management of vitiligo
Minireview Submitted: 27.1.2018 Accepted: 14.3.2018 Conflict of interest None. DOI: 10.1111/ddg.13680 Therapeutic management of vitiligo Rachela Bleuel, Bernadette Eberlein Department Dermatology and Allergy
More informationSTUDY. Association of the Köbner Phenomenon With Disease Activity and Therapeutic Responsiveness in Vitiligo Vulgaris
STUDY Association of the Köbner Phenomenon With Disease Activity and Therapeutic Responsiveness in Vitiligo Vulgaris M. D. Njoo, MD; P. K. Das, MSc, PhD; J. D. Bos, MD, PhD; W. Westerhof, MD, PhD Objective:
More informationAndrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada
Andrei Metelitsa, MD, FRCPC, FAAD Co-Director, Institute for Skin Advancement Clinical Associate Professor, Dermatology University of Calgary, Canada Copyright 2017 by Sea Courses Inc. All rights reserved.
More informationSTUDY. 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis
STUDY 1% Pimecrolimus, 0.005% Calcipotriol, and 0.1% Betamethasone in the Treatment of Intertriginous Psoriasis A Double-blind, Randomized Controlled Study Alexander Kreuter, MD; Anna Sommer, MD; Julia
More informationVitiligo is an acquired cutaneous depigmentation
2017 EDIZIONI MINERVA MEDICA Online version at http://www.minervamedica.it Vitiligo is an acquired cutaneous depigmentation disorder affecting approximately 1% to 2% of the world population with no predilection
More informationVITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY
VITAMIN D AND THE SKIN JOYCE FARAH MD MS FAAD FARAH DERMATOLOGY AND COSMETICS, LLC ASSISTANT PROFESSOR OF MEDICINE AND ENT UPSTATE MEDICAL UNIVERSITY VIT D RECEPTORS ROLE IN MAINTAINING NORMAL FOLLICULAR
More informationACTIVE.LITE. Patent-Pending Technology + Visibly Perceivable Results in Less than 14 Days. Tomorrow s Vision Today!
ACTIVE.LITE Patent-Pending Technology + Visibly Perceivable Results in Less than 14 Days Tomorrow s Vision Today! AESTHETIC PERFECTION IS THE STANDARD Aesthetic skin perfection is now the consumer standard
More informationSCIENTIFIC PAPER ABSTRACT
SCIENTIFIC PAPER ABSTRACT Vitiligo Treatment with Monochromatic Excimer Light and Tacrolimus: Results of an Open Randomized Controlled Study Nistico` S., Chiricozzi A., M.D., Rosita Saraceno R., Schipani
More informationCorrespondence should be addressed to Amir Kalafi;
ISRN Dermatology, Article ID 472546, 6 pages http://dx.doi.org/10.1155/2014/472546 Clinical Study Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo:
More informationCorporate Medical Policy
Corporate Medical Policy Light Therapy for Dermatologic Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: light_therapy_for_dermatologic_conditions 5/2012 11/2017 11/2018
More informationTreatment Recalcitrant Vitiligo with Narrow Band UVB M J B
Treatment Recalcitrant Vitiligo with Narrow Band UVB Wisam Ali Ameen College of Medicine, University of Babylon, Hilla, Iraq. M J B Abstract Background: Vitiligo is a common and chronic disease with a
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationClinical Study A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma
Dermatology Research and Practice Volume 2011, Article ID 379173, 5 pages doi:10.1155/2011/379173 Clinical Study A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the
More informationTopical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases
Topical Tacrolimus for Parastomal Pyoderma Gangrenosum: A Report of Two Cases Maria Altieri, MS; Khashayar Vaziri, MD; and Bruce A. Orkin, MD Abstract Pyoderma gangrenosum (PG) is an idiopathic, ulcerative,
More informationNarrow-band UVB PHOTOTHERAPY for Skin Diseases
Narrow-band UVB PHOTOTHERAPY for Skin Diseases By Dr. Manal Bosseila Cairo University, Egypt HISTORICAL ASPECT In 1978: Irradiation cabin with broad band UVB tubes was introduced for psoriasis & uremic
More informationPsoriasis is a lifelong condition, with onset
THERAPEUTICS FOR THE CLINICIAN Clobetasol Propionate Lotion in the Treatment of Moderate to Severe Plaque-Type Psoriasis Jacques Decroix, MD; Henrik Pres, MD; Nicolaï Tsankov, MD; Michel Poncet, PhD; Stéphanie
More informationEpidemiological study, clinical spectrum and associations of childhood vitiligo in a tertiary care centre
International Journal of Research in Dermatology Murugaiyan R. Int J Res Dermatol. 2016 Dec;2(4):86-90 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20163976
More informationالاكزيماتيد= Eczematid
1 / 7 2 / 7 Pityriasis Debate confusing of hypopigmentation characterized increasing surrounded differ hypomelanotic "progressive exists alba misnomer extensive a to observed term the applied term derived
More informationIgG. IgG. narrow-band UVB co-culture. E- P-cadherin PCNA. Abstract Vitiligo vulgaris is an acquired
行 : B IgG (3/3) Title: Effects of narrow-band UVB and IgG antibodies from patients with vitiligo vulgaris on migrationproliferation and melanogenesis in melanocytes and melanoblasts (3/3) : NSC 93-2314-B002-070
More informationNovan Provides Update on SB414 Inflammatory Skin Disease Development Program
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program SB414 Nitric Oxide-Releasing Cream Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting
More informationA Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients
Volume 1, Issue 3 Research Article A Retrospective Study on the Risk of Non-Melanoma Skin Cancer in PUVA and Narrowband UVB Treated Patients Darukarnphut P, Rattanakaemakorn P *, Rajatanavin N Division
More informationShort-term Effects of 308-nm Xenon-chloride Excimer Laser and Narrow-band Ultraviolet B in the Treatment of Vitiligo: A Comparative Study
J Korean Med Sci 2005; 20: 273-8 ISSN 1011-8934 opyright The Korean cademy of Medical Sciences Short-term Effects of 308-nm Xenon-chloride Excimer Laser and Narrow-band Ultraviolet in the Treatment of
More informationProgressive Macular Hypomelanosis in Korean Patients: A Clinicopathologic Study
Ann Dermatol Vol. 2, No., 2009 ORIGINAL ARTICLE Progressive Macular Hypomelanosis in Korean Patients: A Clinicopathologic Study Seon Wook Hwang, M.D., Soon Kwon Hong, M.D., Sang Hyun Kim, M.D., Jeong Hoon
More informationCurrent and emerging therapy for the management of vitiligo
REVIEW Current and emerging therapy for the management of vitiligo Alicia Cecile Borderé Jo Lambert Nanny van Geel University Hospital of Ghent, Department of Dermatology, Ghent, Belgium Correspondence:
More information308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study
Original Article 308-nm excimer laser plus topical calcipotriol in the treatment of vitiligo; A single blind randomized clinical study Hassan Seirafi, MD 1 Maryam Daneshpazhouh, MD 1 Somayeh Khezri, MD
More informationEffect of intralesional platelet rich plasma in chronic localized vitiligo
International Journal of Research in Dermatology Mahajan R et al. Int J Res Dermatol. 2018 Nov;4(4):550-555 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20183464
More informationSkin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationIt is estimated that about 26,000 new cases of
Focus on CME at Dalhousie University Set On Soothing Psoriasis A. H. Murray, MD, FRCP(C) Presented at the 76th Annual Dalhousie Refresher Course It is estimated that about 26,000 new cases of psoriasis
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Psoriasis (excluding widespread plaque psoriasis) Psoriasis is a common chronic skin disorder. Estimates of the prevalence (proportion
More informationVitiligo is an acquired cutaneous depigmentation disorder
SCHOOL IN PHOTODERMATOLOGY SECTION EDITOR: RIK ROELANDTS Photo(chemo)therapy for vitiligo Alessia Pacifico & Giovanni Leone Photodermatology Unit, San Gallicano Dermatological Institute, Roma, Italy Summary
More informationPrescribing Information
Prescribing Information Pr DERMOVATE Cream (clobetasol propionate cream, USP) Pr DERMOVATE Ointment (clobetasol propionate ointment, USP) Topical corticosteroid TaroPharma Preparation Date: A Division
More informationFrequently Asked Questions
1112:V15:05:PB1540 Frequently Asked Questions For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Dear Doctor, Warm regards from Cipla Xterna!!! We, at Cipla Xterna, a dedicated
More informationTrichloroacetic Acid Peel 15% + NB-UVB Versus Trichloroacetic Acid Peel 25% + NB-UVB for Stable Non-Segmental Vitiligo
Med. J. Cairo Univ., Vol. 84, No. 1, September: 959-963, 2016 www.medicaljournalofcairouniversity.net Trichloroacetic Acid Peel 15% + NB-UVB Versus Trichloroacetic Acid Peel 25% + NB-UVB for Stable Non-Segmental
More informationVITILIGO. Made by: Basma Noor, Maryam Mahjoub, Irin Chankao and Sara Samadi.
VITILIGO Made by: Basma Noor, Maryam Mahjoub, Irin Chankao and Sara Samadi. What is Vitiligo? Vitiligo is a chronic skin disease (a long-lasting condition that can be controlled but not cured) characterized
More informationKeywords: Psoriasis vulgaris Zinc pyrithione Betamethasone dipropionate
CLINICAL EFFICACY AND SAFETY OF A COMBINED FORMULATION OF ZINC PYRITHIONE 0.25% AND BETAMETHASONE DIPROPIONATE MICRONIZED 0.05% IN THE TREATMENT OF MILD TO MODERATE PLAQUE PSORIASIS. Abstract Background
More informationCutaneous Conditions Associated with Systemic Disease
Cutaneous Conditions Associated with Systemic Disease Johnnie M Woodson, M.D., F.A.A.D. Assistant Professor of Dermatology University of Nevada School of Medicine Director of J. Woodson Dermatology & Associates,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationVitiligo EPIDEMIOLOGY
Vitiligo EPIDEMIOLOGY Vitiligo occurs worldwide, with a prevalence of 0.1 percent to 2.0 percent. In the United States, the estimated incidence is 1 percent. Vitiligo commonly begins in childhood or young
More informationMaking decisions about available treatments
TREATMENTS Making decisions about available treatments The aim of this ebooklet is to help you think through the choices that are available to you. It includes: the factors which might influence your decisions.
More informationComparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial
Received: 10.7.2011 Accepted: 5.12.2011 Original Article Comparison of the narrow band UVB versus systemic corticosteroids in the treatment of lichen planus: A randomized clinical trial Fariba Iraji, 1
More informationStudy of the Serum Level of the Monokine Induced by Interferon Gamma (MIG) in Vitiligo Patients
ORIGINAL ARTICLE Study of the Serum Level of the Monokine Induced by Interferon Gamma (MIG) in Vitiligo Patients Zeinab A. Ibrahim, MD, 1 Shereen F. Gheida, MD, 1 Amal S. Elbndary, MD, 2 Rabab R. Abdelsalam,
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationVitiligo: How many types?
Vitiligo Evidence Based Update, Holywell Park, Loughborough, 23 May 2013 Vitiligo: How many types? Alain Taïeb Dept of Dermatology and Pediatric Dermatology National Reference Centre for Rare Skin Disorders,
More informationNew and Experimental Treatments of Vitiligo and Other Hypomelanoses
Dermatol Clin 25 (2007) 393 400 New and Experimental Treatments of Vitiligo and Other Hypomelanoses Torello Lotti, MD*, Francesca Prignano, MD, Gionata Buggiani, MD Department of Dermatological Sciences,
More informationTherapeutic Effects of 0.1% Tacrolimus Eye Drops for Refractory Vernal Keratoconjunctivitis
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 3 Ver. VI (Mar. 2016), PP 44-48 www.iosrjournals.org Therapeutic Effects of 0.1% Tacrolimus
More informationChemical structure of calcipotriol
PRODUCT INFORMATION DAIVONEX CREAM AUST R 57354 Calcipotriol 50 microgram/g NAME OF THE MEDICINE: CALCIPOTRIOL DESCRIPTION Calcipotriol is a white or almost white crystalline substance. It is a vitamin
More information15 Immunodeficiencies
15 Immunodeficiencies A. Acquired causes of immunodeficiencies 1. Environmental (UV irradiation) 2. Drug induced (immunosuppressants) 3. non-hiv Viral (measles virus) Dr. Andrea Hubbard School of Pharmacy
More informationTHE TREATMENT OF VITILIGO WITH AMMI MAJUS LINN*
THE TREATMENT OF VITILIGO WITH AMMI MAJUS LINN* A PRELIMINARY NOTE EDWIN SIDI, M.D. AND J. BOURGEOIS-GAVARDIN, M.D. Paris, France At the suggestion of our Egyptian colleagues we have used an extract of
More informationReview Article. Narrow band UVB phototherapy in dermatology
Review Article Narrow band UVB phototherapy in dermatology Sunil Dogra, Amrinder Jit Kanwar Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education & Research,
More informationService Line: Rapid Response Service Version: 1.0 Publication Date: October 11, 2017 Report Length: 21 Pages
CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Tacrolimus for the Treatment of Adults with Psoriasis or Vitiligo: A Review of the Clinical and Cost-Effectiveness Service Line: Rapid Response
More informationDermaPep A530. Multifunctional anti-inflammatory peptide for irritated and sensitive skin. Experience The Magic of Science
Experience The Magic of Science DermaPep A53 Multifunctional anti-inflammatory peptide for irritated and sensitive skin DermaP ep Experience the magic of science Anti-aging DermaPep A35 DermaPep A42 DermaPep
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More informationTreatment of Vitiligo by Narrow Band UVB Radiation alone in Comparison to Combination
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-853, p-issn: 2279-861.Volume 14, Issue 12 Ver. VI (Dec. 15), PP 63-68 www.iosrjournals.org Treatment of Vitiligo by Narrow Band UVB
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationEpidemiological aspects and disease association of childhood vitiligo
Original Article Epidemiological aspects and disease association of childhood S. Farajzadeh*, M. Aflatoonian*, S. Mohammadi*, B. Vares*, R. Amiri* * Department of Dermatology, Afzalipour hospital Kerman
More informationPrescribing Information. Taro-Clobetasol. Taro-Clobetasol
Prescribing Information Pr Taro-Clobetasol Clobetasol Propionate Cream USP, 0.05% w/w Pr Taro-Clobetasol Clobetasol Propionate Ointment USP, 0.05% w/w Therapeutic Classification Topical corticosteroid
More informationThursday, 21 October :53 - Last Updated Thursday, 11 November :27
1 / 15 2 / 15 3 / 15 4 / 15 Pityriasis Alba Background Pityriasis alba is a nonspecific dermatitis of unknown etiology that causes erythematous scaly patches. These resolve and leave areas of hypopigmentation
More informationDepartment of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, , India. What s already known about this topic?
CLINICAL AND LABORATORY INVESTIGATIONS BJD British Journal of Dermatology Comparison between autologous noncultured extracted hair follicle outer root sheath cell suspension and autologous noncultured
More informationComparing the efficacy of topical clobetasol 0.05% plus 5FU 5% cream vs. topical clobetasol 0.05% alone in treatment of vitiligo
Original article Comparing the efficacy of topical clobetasol 0.05% plus 5FU 5% cream vs. topical clobetasol 0.05% alone in treatment of vitiligo Zabihollah Shahmoradi 1, Fatemeh Mokhtari 2, Gita Faghihi
More informationClinical Trial Report Synopsis
Clinical Trial Report Synopsis A phase 2a, proof of concept trial, testing twice daily application of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis Design of trial:
More informationPsoriasis: Causes, Symptoms, And Treatment
Psoriasis: Causes, Symptoms, And Treatment We all know that a healthy immune system is good. But, do you know that an overactive immune system can cause certain conditions like Psoriasis? Read on to find
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationClinical Course of Segmental Vitiligo: A Retrospective Study of Eighty-Seven Patients
Ann Dermatol Vol. 26, No. 1, 2014 http://dx.doi.org/10.5021/ad.2014.26.1.61 ORIGINAL ARTICLE Clinical Course of Segmental Vitiligo: A Retrospective Study of Eighty-Seven Patients Ji-Hye Park, Mi-Young
More informationActa Medica Marisiensis 2018;64(1):17-21
Acta Medica Marisiensis 2018;64(1):17-21 DOI: 10.2478/amma-2018-0003 RESEARCH ARTICLE Clinical and Therapeutic Trial for the Efficacy of Narrow Band - UVB Phototherapy versus Systemic Therapy in Moderate
More information...: acrodermatitis continua
Appendix Index Index...: acrodermatitis continua 217-219 age of onset of AD 10 allergens - aeroallergens 38, 68, 69 - allergen avoidance 68 - autoallergens 30 - food allergens 38, 68 - house-dust mite
More informationMultivariate Analysis of Factors Associated with the Koebner Phenomenon in Vitiligo: An Observational Study of 381 Patients
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 29, No. 3, 2017 https://doi.org/10.5021/ad.2017.29.3.302 ORIGINAL ARTICLE Multivariate Analysis of Factors Associated with the Koebner Phenomenon in Vitiligo:
More informationAvoiding Litigations. Be sure Be safe! - Dom Daniel Editor EXECUTIVE EDITOR & PUBLISHER
EXECUTIVE EDITOR & PUBLISHER Dom Daniel EDITORIAL BOARD Dr. Daniel Lischinsky Dr. Itzhak Vider Dr. Jana Hercogová Dr. Joe Niamtu III Dr. Monica Elman Dr. Neelam A. Vashi Dr. Priti Shukla Dr. Roshni Menon
More informationDiagnosis of breast cancer by analysis of sialic acid concentrations in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles
Nano Res. Electronic Supplementary Material Diagnosis of breast cancer by analysis of sialic acid s in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles Aida Hernández-Arteaga1,
More informationuse of Calcineurin University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010
Safety Issues with the use of Calcineurin Inhibitors Tarek Salem MD Tarek Salem, MD University of Ottawa Canada The 7 th International Congress on Autoimmunity. Ljubljana- Slovenia. May 5-9, 2010 Disclaimer
More informationAN2728 Clinical Data in Atopic Dermatitis
AN2728 Clinical Data in Atopic Dermatitis Karl Beutner, MD, PhD 1 Overview of AN2728 in Atopic Dermatitis Target Product Profile Safe and effective topical therapy for atopic dermatitis Efficacy in the
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationRapid initiation of repigmentation in vitiligo with Dead Sea climatotherapy in combination with pseudocatalase (PC-KUS)
Oxford, IJD International 0011-9059 Blackwell 41 UK Science, Journal Ltd 2002 of Dermatology Report Repigmentation Schallreuter et al. in vitiligo and hydrogen peroxide removal Rapid initiation of repigmentation
More information